Market News & Trends
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program
Cocrystal Pharma, Inc. has selected two investigational novel antiviral drug candidates for further development as oral treatments for SARS-CoV-2, the virus that causes COVID-19…..
TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19
TFF Pharmaceuticals, Inc. recently announced it has completed enrollment of 40 healthy subjects in its Phase 1 clinical trial (CT.gov identifier NCT05168644) of a dry…
PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine
PDS Biotechnology Corporation recently announced preclinical data for its universal flu vaccine, which was shown to be effective against….
Provectus Biopharmaceuticals Provides Update on Research into PV-10 Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better
Provectus recently provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene small molecule) as an immune adjuvant in…
Allergy Therapeutics Announces FDA Clearance of IND Application for Novel Peanut Allergy Vaccine Candidate
Allergy Therapeutics recently announced the US FDA has cleared the Group’s Investigational New Drug application (IND) for its novel virus-like particle (VLP)-based peanut allergy vaccine…
Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading Into Phase 2b in Collaboration With Merck
Evaxion Biotech A/S recently announced the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed….
Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer’s Disease With Vascular Pathology
Cyclerion Therapeutics, Inc. recently announced patient dosing has begun in its Phase 2a study in Alzheimer’s Disease with Vascular Pathology (ADv). “The need for effective…
Hepion Pharmaceuticals’ Rencofilstat, in Combination With an Immune Checkpoint Inhibitor, Demonstrates Synergistic Anti-Tumor Activity in a Nonclinical Liver Cancer Study
Hepion Pharmaceuticals, Inc. recently announced the results of a nonclinical research study showing that its clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor….
Tony O’Neill Joins Ajinomoto Bio-Pharma Services’ Leadership Team as Vice President of Compliance
Ajinomoto Bio-Pharma Services, a leading global provider of bio-pharmaceutical contract development and manufacturing services, is pleased to announce that Tony O’Neill has joined Aji Bio-Pharma…
Catalent Completes $10-Million Expansion of High Potency Micronization Capabilities at US & UK Facilities
Catalent recently announced it has completed a $10-million expansion in state-of-the-art large-scale isolator units at its Malvern, PA, and Dartford, UK, facilities, to provide advanced…
INmune Bio, Inc. Announces Research Collaboration With Chinese University of Hong Kong to Evaluate INKmune in Nasopharyngeal Cancer
INmune Bio, Inc. recently announced the company has entered into a preclinical research collaboration with Chinese University of Hong Kong (CUHK) to evaluate INKmune -…
Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia & Dementia with Lewy Bodies
Athira Pharma, Inc. recently announced patient dosing has begun in SHAPE, a Phase 2 clinical trial of ATH-1017 for the treatment of Parkinson’s disease dementia and Dementia with Lewy bodies….
Sterling Pharma Solutions Expands Early Phase Development Capabilities at Cary, NC, Facility
Sterling Pharma Solutions, a global contract development and manufacturing organization, recently announced it has commenced a $2.1-million expansion project to increase chemical and analytical capabilities…
Monte Rosa Therapeutics & Yeda Announce License & Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders
Monte Rosa Therapeutics, Inc. recently announced a license and research collaboration agreement with Dr. Nir London and the Yeda Research and Development Company Ltd., the…
Biomea Fusion Announces First Patient Dosed
Biomea Fusion, Inc. recently announced the first patient has been dosed in its Phase 1 clinical trial evaluating BMF-219, the company’s irreversible covalent menin inhibitor, in patients with….
FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder
Mind Medicine (MindMed) Inc. recently announced the US FDA has cleared MindMed’s Investigational New Drug application, allowing the company’s Phase 2b dose-optimization trial of….
Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
Checkpoint Therapeutics, Inc. recently announced positive topline results from its registration-enabling clinical trial evaluating the safety and efficacy of its anti-PD-L1 antibody, cosibelimab, administered as…
Genezen Appoints Senior Director of Business Development to Support Rapid Growth
Genezen, Inc., a cell and gene therapy Contract Development and Manufacturing Organization (CDMO) focused on early phase process development, GMP vector production and analytical testing…
Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients
Lyra Therapeutics, Inc. recently announced the initiation of the Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult, surgically naïve chronic rhinosinusitis (CRS) patients, with trial sites open for….
SAB Biotherapeutics Reports Positive Phase 2 Virology Data Demonstrating SAB-185 Met Criteria for Advancement to Phase 3 in NIH ACTIV-2 Trial for Treatment of COVID-19
SAB Biotherapeutics recently reported positive Phase 2 safety and efficacy data demonstrating that SAB-185 met the criteria required for advancement to Phase 3 in the…
